litlas
ログインアカウント作成

Walter M. Stadler

1994–2026 年に発表

158
論文数
35,665
被引用数
95
h 指数
155
i10 指数

被引用数

Walter M. Stadler の年別被引用数1956 年: 被引用 1 件1984 年: 被引用 1 件1988 年: 被引用 1 件1991 年: 被引用 1 件1994 年: 被引用 3 件1995 年: 被引用 3 件1996 年: 被引用 15 件1997 年: 被引用 13 件1998 年: 被引用 40 件1999 年: 被引用 42 件2000 年: 被引用 56 件2001 年: 被引用 45 件2002 年: 被引用 74 件2003 年: 被引用 71 件2004 年: 被引用 107 件2005 年: 被引用 177 件2006 年: 被引用 233 件2007 年: 被引用 297 件2008 年: 被引用 312 件2009 年: 被引用 373 件2010 年: 被引用 377 件2011 年: 被引用 417 件2012 年: 被引用 386 件2013 年: 被引用 344 件2014 年: 被引用 280 件2015 年: 被引用 218 件2016 年: 被引用 222 件2017 年: 被引用 233 件2018 年: 被引用 268 件2019 年: 被引用 907 件2020 年: 被引用 1,041 件2021 年: 被引用 941 件2022 年: 被引用 717 件2023 年: 被引用 528 件2024 年: 被引用 732 件2025 年: 被引用 364 件2026 年: 被引用 7 件1957〜1983 年は被引用が無いため表示していません1985〜1987 年は被引用が無いため表示していません1989〜1990 年は被引用が無いため表示していません1992〜1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,054 件、この内訳の 28.7%中国: 引用元論文 1,131 件、この内訳の 8%イギリス: 引用元論文 916 件、この内訳の 6.5%イタリア: 引用元論文 817 件、この内訳の 5.8%フランス: 引用元論文 745 件、この内訳の 5.3%ドイツ: 引用元論文 740 件、この内訳の 5.2%カナダ: 引用元論文 608 件、この内訳の 4.3%スペイン: 引用元論文 466 件、この内訳の 3.3%日本: 引用元論文 456 件、この内訳の 3.2%オランダ: 引用元論文 449 件、この内訳の 3.2%オーストラリア: 引用元論文 330 件、この内訳の 2.3%スイス: 引用元論文 305 件、この内訳の 2.1%
0%28.7%その他 22.1%

機関

分野

  • Medicine72.5%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology2.5%
  • Engineering0.9%
  • Mathematics0.7%
  • Computer Science0.4%
  • その他2.1%

トピック

  • Renal cell carcinoma treatment6.9%
  • Cancer Immunotherapy and Biomarkers5.1%
  • Prostate Cancer Treatment and Research5%
  • Bladder and Urothelial Cancer Treatments3.6%
  • Prostate Cancer Diagnosis and Treatment3%
  • Cancer Genomics and Diagnostics2.9%
  • その他73.5%

共著者

全論文

検索で開く
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    著者: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 被引用: 1,603

  2. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    著者: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 被引用: 1,250

  3. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    著者: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 被引用: 1,010

  4. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

    著者: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin - European Urology 2018 被引用: 619

  5. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    著者: Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. Naomi Horiba, Sreenivasa Nattam, Robert Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany Sleckman, Heinz‐Josef Lenz, Patrick J. Stiff, Pankaj Kumar, Peng Xu, Les Henderson, Naoko Takebe, Ravi Salgia, Xi Wang, Walter M. Stadler, Frédéric J. de Sauvage, Hedy L. Kindler - Journal of Clinical Oncology 2015 被引用: 544

  6. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

    著者: Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence, Robert J. Motzer, Bradley A. McGregor, Richard J. Lee, Rohit Jain, Nancy B. Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda-Sánchez, Robert A. Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier - JAMA Oncology 2022 被引用: 142

  7. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    著者: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski - New England Journal of Medicine 2007 被引用: 4,784

  8. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

    著者: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross‐Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry Nosov, Camillo Porta, Jae‐Lyun Lee, Xavier García del Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, He Li, Aobo Wang, Rodolfo F. Perini, Donna Vickery, Laurence Albigès, Brian I. Rini - New England Journal of Medicine 2024 被引用: 142

  9. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

    著者: Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Oudard, Paweł Wiechno, Bożena Kukiełka-Budny, Vladimír Šámal, Jaroslav Hájek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csőszi, Zoran Filipovic, Frederico Gonçalves, А А Прохоров, Eric Cheung, Arif Hussain, Nuno Sousa, Amit Bahl, Syed A. Hussain, Harald Fricke, Pavla Kadlecová, Tomáš Scheiner, Roman Korolkiewicz, Jiřina Bartůňková, Radek Špíšek, VIABLE Investigators, Walter M. Stadler, Arthur Berg, Karl‐Heinz Kurth, Celestia S. Higano, Matti Aapro, Michael Krainer, Stephan Hruby, Johannes Meran, S. Polyakov, Jean‐Pascal Machiels, Thierry Roumeguère, Koen Ackaert, Nicolaas Lumen, Thierry Gil, Velko Minchev, Antoaneta Tomova, Borislav D. Dimitrov, Marchela Koleva, Antonio Juretić, Ana Fröbe, Željko Vojnović, Martin Drabek, L. Jarolím, Tomáš Büchler, Eva Kindlová, Jan Schraml, Milada Zemanová, Prausova Jana, Bohuslav Melichar, Martina Chodacká, Jan Jansa, Gedske Daugaard, Nicolas Delonchamps, Brigitte Duclos, Stéphane Culine, G. Deplanque, Sylvestre Le Moulec, Peter Hammerer, Gerald Rodemer, Manuel Ritter, Axel S. Merseburger, Marc‐Oliver Grimm, Ilija Damjanoski, Manfred Wirth, Martin Burmester, Kurt Miller, Jan Herden, Bastian Keck, Christian Wuelfing, Alexander Winter, Martin Boegemann, Ingo Kausch von Schmeling, Paolo Fornara, E. Jaeger, G. Bodoky, Zsuzsanna Pápai, Géza Böszörményi-Nagy, Paola Vanella, Héctor Soto Parrà, Rodolfo Passalacqua, Francesco Ferraù, Michele Maio, Lucia Fratino, Enrico Cortesi, Gunta Purkalne, Jolita Asadauskienė, Rasa Jančiauskienė, Skaistė Tulytė, Alvydas Česas, Marco B. Polée, Brigitte C.M. Haberkorn, Fons van de Eertwegh, Pieter van den Berg ほか 83 名 - JAMA Oncology 2022 被引用: 90

  10. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    著者: Andrew J. Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, Sadie Oberg, Daniel J. George - The Lancet Oncology 2016 被引用: 424

  11. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    著者: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 被引用: 638

  12. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

    著者: Laurence Albigès, Brian I. Rini, Katriina Peltola, G.A. De Velasco Oria, Mauricio Burotto, C. Suarez Rodriguez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, M. Gumus, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, Andrew Z. Wang, R. Perini, Donna Vickery, T.B. Powles, Toni K. Choueiri - Annals of Oncology 2023 被引用: 53

  13. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

    著者: Toni K. Choueiri, Mayer Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet M. Kluger, Walter M. Stadler, José Luis Perez‐Gracia, Douglas G. McNeel, Brendan D. Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard L. Appleman, Lawrence Fong, Laurence Albigès, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross‐Macdonald, Shivani Srivastava, Maria Jure–Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol - Clinical Cancer Research 2016 被引用: 292

  14. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

    著者: Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado-González, Takeo Kosaka, Walter M. Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia‐Hsin Ju, Corbin G. Thompson, Ana M. Aparicio - Journal of Clinical Oncology 2024 被引用: 28

  15. Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

    著者: Randy F. Sweis, Stefani Spranger, Riyue Bao, Gladell P. Paner, Walter M. Stadler, Gary D. Steinberg, Thomas F. Gajewski - Cancer Immunology Research 2016 被引用: 350

  16. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

    著者: Noura J. Choudhury, Alexa Campanile, Tatjana Antic, Kai Lee Yap, Carrie Fitzpatrick, James L. Wade, Theodore Karrison, Walter M. Stadler, Yusuke Nakamura, Peter H. O’Donnell - Journal of Clinical Oncology 2016 被引用: 167

  17. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

    著者: Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz - Clinical Cancer Research 2022 被引用: 46

  18. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

    著者: Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain - Journal of Clinical Oncology 2018 被引用: 181

  19. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    著者: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofilena, Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski - Journal of Clinical Oncology 2009 被引用: 1,083

  20. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

    著者: Maha Hussain, Stephanie Daignault‐Newton, Przemyslaw Twardowski, Costantine Albany, Mark N. Stein, Lakshmi P. Kunju, Javed Siddiqui, Yi-Mi Wu, Dan R. Robinson, Robert J. Lonigro, Xuhong Cao, Scott A. Tomlins, Rohit Mehra, Kathleen A. Cooney, Bruce Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Paul G. Corn, Young E. Whang, David C. Smith, Megan E.V. Caram, Karen E. Knudsen, Walter M. Stadler, Felix Y. Feng, Arul M. Chinnaiyan - Journal of Clinical Oncology 2017 被引用: 210

  21. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

    著者: Rana R. McKay, Bradley A. McGregor, Wanling Xie, David A. Braun, Xiao X. Wei, Christos E. Kyriakopoulos, Yousef Zakharia, Benjamin L. Maughan, Tracy L. Rose, Walter M. Stadler, David F. McDermott, Lauren C. Harshman, Toni K. Choueiri - Journal of Clinical Oncology 2020 被引用: 105

  22. Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

    著者: William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John F. Mahoney, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, J. Paul Monk, Ellen B. Kaplan, Nicholas J. Vogelzang, Eric J. Small - Journal of Clinical Oncology 2012 被引用: 483

  23. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    著者: Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice P. Dutcher, Eric J. Small - Journal of Clinical Oncology 2008 被引用: 908

  24. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

    著者: Matthew R. Smith, Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas J. Vogelzang, Walter M. Stadler, Ralph J. Hauke, J. Paul Monk, Philip J. Saylor, Nirmala Bhoopalam, Fred Saad, Ben L. Sanford, William Kevin Kelly, Michael J. Morris, Eric J. Small - Journal of Clinical Oncology 2014 被引用: 250